TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16100502

Group type: EXPERIMENTAL
Intervention: Home visiting program
Number of subjects: 513
Study: 12053634

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer mood stabilizers or combinations of mood stabilizers
Number of subjects: 0
Study: 9709470

Group type: COMPARATOR
Intervention: Chlorambucil (0.15 mg/kg/day for months 2, 4, and 6) and steroids (1 g methyl‐prednisolone i.v. on three consecutive days, followed by oral prednisone 0.5 mg/kg/day for months 1, 3, and 5)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (1.5‐2.0 mg/kg/day for 1 year) and steroids in a comparable dose
Number of subjects: 32
Study: 8701523

Group type: EXPERIMENTAL
Intervention: Nasal cannula
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hudson face mask
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 32
Study: 1870651

Group type: EXPERIMENTAL
Intervention: Compulsory inpatient treatment
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Compulsory attendance at Alcoholics Anonymous (AA) meetings
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Choice of treatment options
Number of subjects: 227
Study: 6314140

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at 0.1 microgram per kilogram per minute
Number of subjects: 6

Group type: COMPARATOR
Intervention: Isoproterenol infusion at 0.02 micrograms per kilogram per minute
Number of subjects: 6

Group type: COMPARATOR
Intervention: Epinephrine infusion at 0.05 micrograms per kilogram per minute after administration of ICI 118551 (2.5 or 5 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Epinephrine infusion after placebo
Number of subjects: 6
Study: 30676772

Group type: EXPERIMENTAL
Intervention: T2* weighted MRI
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: T2 weighted MRI
Number of subjects: 10

Group type: COMPARATOR
Intervention: CT
Number of subjects: 10
Study: 27726259

Group type: EXPERIMENTAL
Intervention: Programmed sports therapy (PST) for 6 months
Number of subjects: 64
Study: 26916684

Group type: EXPERIMENTAL
Intervention: Metformin (1 g twice daily)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study: 25231896

Group type: EXPERIMENTAL
Intervention: Mirogabalin 5 mg/day
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Mirogabalin 10 mg/day
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg/day
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Mirogabalin 20 mg/day
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Mirogabalin 30 mg/day
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 452

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study: 21769661

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 50

Group type: COMPARATOR
Intervention: Combined vertebroplasty with antiresorptive agent
Number of subjects: 50
Study: 19111278

Group type: EXPERIMENTAL
Intervention: d‐amphetamine (20 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 17764549

Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Preliminary intervention
Number of subjects: 24
Study: 14693537

Group type: EXPERIMENTAL
Intervention: 300 mg lamivudine once daily
Number of subjects: 60
Study: 11898726

Group type: EXPERIMENTAL
Intervention: isoptine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhythmonorm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: allapinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: allapinin, rhythmonorm, isoptine
Number of subjects: 0
Study: 9825192

Group type: EXPERIMENTAL
Intervention: Ramipril treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 8138400

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 1670617

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 7071166

Group type: EXPERIMENTAL
Intervention: Compression bandages worn for eight hours
Number of subjects: 146

Group type: COMPARATOR
Intervention: Compression bandages worn for three weeks
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Pressure under the bandage applied at the end of the operation
Number of subjects: 146
Study: 29241345

Group type: EXPERIMENTAL
Intervention: Internal focus (n = 22)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: External focus (n = 22)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (n = 21)
Number of subjects: 65
Study: 29948457

Group type: EXPERIMENTAL
Intervention: Q‐switched KTP 532‐nm nanosecond laser
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: KTP 532‐nm picosecond laser
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study: 27041454

Group type: EXPERIMENTAL
Intervention: Delirium
Number of subjects: 66

Group type: COMPARATOR
Intervention: No Delirium
Number of subjects: 66
Study: 25609853

Group type: EXPERIMENTAL
Intervention: Cervical manipulation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thoracic manipulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo SM (control group)
Number of subjects: 30
Study: 21070222

Group type: EXPERIMENTAL
Intervention: BNC (NT-proBNP guided care)
Number of subjects: 190

Group type: COMPARATOR
Intervention: UC (Usual Care)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: HNC (Home-based Nurse Care)
Number of subjects: 190
Study: 19206035

Group type: EXPERIMENTAL
Intervention: Fractionated inpatient rehabilitation (three weeks and another week at a future date)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Four-week inpatient treatment
Number of subjects: 0
Study: 17924971

Group type: EXPERIMENTAL
Intervention: Capillary blood samples
Number of subjects: 61

Group type: COMPARATOR
Intervention: Venous blood samples
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Venous blood stimulated with PHA
Number of subjects: 61

Group type: COMPARATOR
Intervention: Capillary blood stimulated with PHA
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Capillary blood
Number of subjects: 61

Group type: COMPARATOR
Intervention: Venous blood
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Capillary blood stimulated with PAM3Cys and PPD
Number of subjects: 61

Group type: COMPARATOR
Intervention: Venous blood stimulated with PAM3Cys and PPD
Number of subjects: 61
Study: 15207897

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 932
Study: 12207834

Group type: EXPERIMENTAL
Intervention: 3 g cis‐9,trans‐11-trans‐10,cis‐12 isomeric blend (50 : 50) CLA
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 3 g cis‐9,trans‐11-trans‐10,cis‐12 isomeric blend (80 : 20) CLA
Number of subjects: 51

Group type: COMPARATOR
Intervention: linoleic acid (control)
Number of subjects: 51
Study: 9510003

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8077528

Group type: EXPERIMENTAL
Intervention: Postdischarge to 6-month incidence of nonfatal reinfarction
Number of subjects: 8907

Group type: EXPERIMENTAL
Intervention: Cardiac ineligibility for exercise test
Number of subjects: 8907

Group type: EXPERIMENTAL
Intervention: Previous myocardial infarction
Number of subjects: 8907

Group type: EXPERIMENTAL
Intervention: Angina at follow-up
Number of subjects: 8907

Group type: EXPERIMENTAL
Intervention: History of angina (in 6,580 patients with echocardiographic and electrocardiographic monitoring)
Number of subjects: 8907
Study: 2466454

Group type: EXPERIMENTAL
Intervention: Krypton red laser photocoagulation
Number of subjects: 144
Study: 31932108

Group type: EXPERIMENTAL
Intervention: Pazopanib 600 mg once daily and fosbretabulin 54 mg/m2 on days 1, 8, and 15 (phase 1b)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pazopanib 600 mg once daily and fosbretabulin 54 mg/m2 (experimental arm)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Pazopanib 800 mg once daily (control arm)
Number of subjects: 33
Study: 31300995

Group type: EXPERIMENTAL
Intervention: Caregivers of gastroparesis patients
Number of subjects: 47

Group type: COMPARATOR
Intervention: Caregivers of GERD patients
Number of subjects: 47

Group type: COMPARATOR
Intervention: Caregivers of healthy volunteers (HVs)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Overall caregiver burden
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Presence of gastroparesis and other comorbidities
Number of subjects: 47
Study: 28285280

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (60 s)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (60 s) with ergometrine (500 µg)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Early cord clamping (10 s)
Number of subjects: 78
Study: 26081658

Group type: EXPERIMENTAL
Intervention: Anti-TNF treatment
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sclerostin levels
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Radiographic scores (mSASSS)
Number of subjects: 75
Study: 24307311

Group type: EXPERIMENTAL
Intervention: Chaiqin Chengqi Decoction (CQCQD) administered by gastric perfusion (50 mL/2 h) and retention enema (200 mL/6 h) for 7 days
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 35
Study: 21876349

Group type: EXPERIMENTAL
Intervention: Bindarit (1,200 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 19236643

Group type: COMPARATOR
Intervention: 0 mg x kg(‐1) propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.5 mg x kg(‐1) propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 mg x kg(‐1) propofol
Number of subjects: 60
Study: 15992791

Group type: EXPERIMENTAL
Intervention: Artificial language input with multiple generalizations
Number of subjects: 2
Study: 12631162

Group type: EXPERIMENTAL
Intervention: Internal derangement of the TMJ
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Raised muscle tenderness of the temporomandibular system
Number of subjects: 30
Study: 11129620

Group type: EXPERIMENTAL
Intervention: Midazolam-fentanyl (group M) - intravenous midazolam 0.1 mg.kg‐1.h‐1 and fentanyl 25 micrograms.kg‐1 until sternotomy
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propofol-fentanyl (group P) - intravenous propofol 4 mg.kg‐1.h‐1 and fentanyl 25 micrograms.kg‐1 until sternotomy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 16
Study: 9085210

Group type: EXPERIMENTAL
Intervention: Hexoprenaline (10 micrograms administered intravenously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 8239010

Group type: EXPERIMENTAL
Intervention: 2 micrograms/kg clonidine
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 4 micrograms/kg clonidine
Number of subjects: 105

Group type: COMPARATOR
Intervention: 0.4 mg/kg diazepam
Number of subjects: 105

Group type: COMPARATOR
Intervention: 0.03 mg/kg oral atropine
Number of subjects: 105
Study: 3010028

Group type: EXPERIMENTAL
Intervention: Atenolol (beta 1-blocker, 50 mg once per day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: ICI 118,551 (beta 2-blocker, 20 mg t.i.d.)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: ICI 118,551 (beta 2-blocker)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Atenolol (beta 1-blocker)
Number of subjects: 17
Study: 30766555

Group type: EXPERIMENTAL
Intervention: Walking for 30 minutes, 3 days per week for 12 weeks on treadmills
Number of subjects: 115

Group type: COMPARATOR
Intervention: Usual activities (Control)
Number of subjects: 115
Study: 28077539

Group type: COMPARATOR
Intervention: Group R (remifentanil 0.30 µg kg‐1 min‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group B (remifentanil 0.30 µg kg‐1 min‐1 and pre‐anaesthesia butorphanol 20 µg kg‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group BF (remifentanil 0.30 µg kg‐1 min‐1 and pre‐anaesthesia butorphanol 10 µg kg‐1 combined with flurbiprofen axetil 0.5 mg kg‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group S (sufentanil 0.30 µg kg‐1)
Number of subjects: 120
Study: 25591645

Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 62

Group type: COMPARATOR
Intervention: Comparison group (no cerebrolysin)
Number of subjects: 62
Study: 22729798

Group type: EXPERIMENTAL
Intervention: Isometric exercise (50% maximal voluntary contraction) during 1 min coronary balloon occlusion
Number of subjects: 65

Group type: COMPARATOR
Intervention: Non-exercise group (sedentary during coronary occlusion)
Number of subjects: 65
Study: 20716014

Group type: EXPERIMENTAL
Intervention: Specialist Nurse Support (N = 41)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) (N = 39)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Usual Care (Control) (N = 41)
Number of subjects: 121
Study: 17627739

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day
Number of subjects: 684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 684
Study: 15672306

Group type: EXPERIMENTAL
Intervention: Mixed model analysis
Number of subjects: 30285

Group type: EXPERIMENTAL
Intervention: Random effects meta-analysis
Number of subjects: 30285

Group type: COMPARATOR
Intervention: Fixed effects model
Number of subjects: 30285

Group type: EXPERIMENTAL
Intervention: Mixed model
Number of subjects: 30285

Group type: COMPARATOR
Intervention: Linear model
Number of subjects: 30285
Study: 11823755

Group type: EXPERIMENTAL
Intervention: 5 mg olanzapine with 500 mg probenecid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1 mg risperidone with 500 mg probenecid
Number of subjects: 12

Group type: COMPARATOR
Intervention: 5 mg olanzapine alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: 1 mg risperidone alone
Number of subjects: 12
Study: 10027031

Group type: COMPARATOR
Intervention: Propofol infusion, 30 mg.kg‐1.h‐1 (Group P; n = 12)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ketamine bolus, 0.5 mg i.v. followed by propofol infusion, 30 mg.kg‐1.h‐1 (Group PK0.5; n = 12)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ketamine bolus, 0.75 mg i.v. followed by propofol infusion, 30 mg.kg‐1.h‐1 (Group PK0.75; n = 12)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ketamine bolus, 0.25 mg i.v. followed by propofol infusion, 30 mg.kg‐1.h‐1 (Group PK0.25; n = 12)
Number of subjects: 48
Study: 7717488

Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg.kg-1
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ketamine/midazolam 2 mg.kg-1 after midazolam pretreatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ketamine/esmolol 2 mg.kg-1 with esmolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no ketamine)
Number of subjects: 24
Study: 2030491

Group type: EXPERIMENTAL
Intervention: Oral micronized P4 supplementation (200 mg four times daily)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 34
Study: 7211972

Group type: EXPERIMENTAL
Intervention: Ambulation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 14
Study: 31612263

Group type: EXPERIMENTAL
Intervention: Transtibial (TT) technique
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Transportal (TP) technique
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Outside-in (OI) technique
Number of subjects: 86
Study: 31922707

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention delivered in the first year postpartum
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 170
Study: 27514319

Group type: EXPERIMENTAL
Intervention: Angio-Seal (femoral access)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Radial approach
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Angio-Seal
Number of subjects: 240
Study: 25034200

Group type: EXPERIMENTAL
Intervention: Combined standard PCNL and mini‐PCNL (group 1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Combined standard PCNL and RIRS (group 2)
Number of subjects: 45
Study: 24379596

Group type: EXPERIMENTAL
Intervention: Perirenal space blocking (PSB) + specialized medical therapy (SMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No perirenal space blocking (NPSB) + specialized medical therapy (SMT)
Number of subjects: 40
Study: 21210281

Group type: COMPARATOR
Intervention: Task-related oxygen uptake during ADLs in CHF patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Getting dressed in CHF patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sweeping the floor in CHF patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Peak ventilation and peak heart rate during ADLs in CHF patients
Number of subjects: 23
Study: 19725854

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (healthy patients)
Number of subjects: 24
Study: 17410506

Group type: EXPERIMENTAL
Intervention: Transcutaneous electric nerve stimulation (TENS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Patient-controlled intravenous morphine
Number of subjects: 40
Study: 15199619

Group type: EXPERIMENTAL
Intervention: Modified Wuzi Yanzong Granule (MWYG)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ginkgo leaf extraction
Number of subjects: 44
Study: 11893342

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of epoetin (recombinant human erythropoietin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimal reduction (10%) in epoetin dose
Number of subjects: 0
Study: 9810889

Group type: EXPERIMENTAL
Intervention: Elase ointment (proteolytic ointment)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Fibrinolysin
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: DNAse
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (ointment vehicle)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Complete ointment (Elase)
Number of subjects: 84
Study: 7701449

Group type: EXPERIMENTAL
Intervention: 800 micrograms fenoterol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2494014

Group type: EXPERIMENTAL
Intervention: Intravenous lipid emulsion containing medium‐chain triacylglycerols (MCT) and long‐chain triacylglycerols (LCT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional emulsion containing only long‐chain triacylglycerols (LCT)
Number of subjects: 16
Study: 836112

Group type: EXPERIMENTAL
Intervention: 125 IU of human chorionic gonadotropin (HCG) intramuscularly daily for 30 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Diluent only (placebo)
Number of subjects: 11

Group type: COMPARATOR
Intervention: HCG and placebo groups
Number of subjects: 11
Study: 31990912

Group type: EXPERIMENTAL
Intervention: CaFaSpA referral model (intervention)
Number of subjects: 679

Group type: COMPARATOR
Intervention: Usual primary care (control)
Number of subjects: 679
Study: 27693681

Group type: EXPERIMENTAL
Intervention: Intraoperative foot mat use
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control (no foot mat use)
Number of subjects: 127
Study: 25937461

Group type: EXPERIMENTAL
Intervention: MOtiVation and Enhancement (MOVE)
Number of subjects: 51

Group type: COMPARATOR
Intervention: treatment as usual
Number of subjects: 51
Study: 23428878

Group type: EXPERIMENTAL
Intervention: Isocaloric meal with high fiber and antioxidants (vitamin E, selenium, β‐carotene)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isocaloric meal with intermediate fiber and antioxidants (vitamin E, selenium, β‐carotene)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isocaloric meal with low fiber and antioxidants (vitamin E, selenium, β‐carotene)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (baseline measurements before meal)
Number of subjects: 8
Study: 20840349

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50mg twice weekly (BIW)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50mg weekly (QW)
Number of subjects: 752
Study: 19053956

Group type: EXPERIMENTAL
Intervention: Latanoprost with 2% carteolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Latanoprost with 0.5% timolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 15
Study: 17320026

Group type: EXPERIMENTAL
Intervention: Monitoring of surrogate markers (bone mineral density, bone turnover markers, vertebral fracture assessment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surrogate markers for PMO treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integration of surrogate markers in PMO management
Number of subjects: 0
Study: 15311423

Group type: EXPERIMENTAL
Intervention: Public health training on high blood pressure control and obesity reduction
Number of subjects: 400

Group type: COMPARATOR
Intervention: No training
Number of subjects: 400
Study: 11771636

Group type: EXPERIMENTAL
Intervention: Experimental condition where the interviewer contradicted information provided by participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adult participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preschool participants
Number of subjects: 0
Study: 9433573

Group type: EXPERIMENTAL
Intervention: Prior segregation analysis
Number of subjects: 200

Group type: COMPARATOR
Intervention: Linkage only approach
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: All replicates
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Replicates with a major gene found
Number of subjects: 200
Study: 8356499

Group type: EXPERIMENTAL
Intervention: Verres needle technique
Number of subjects: 252

Group type: COMPARATOR
Intervention: Direct insertion technique
Number of subjects: 252
Study: 3306292

Group type: EXPERIMENTAL
Intervention: Org OD 14 (2.5 mg/day for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60